Stephen Evans-Freke is a Non-Executive Director on the Board of ADC Therapeutics, as well as Co-Founder and Managing General Partner of Auven Therapeutics.
Mr. Evans-Freke has been associated with the biotechnology industry for over 35 years as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, Amgen, Centocor, and a number of other leading biotech companies. During this period, Mr. Evans-Freke served as President of PaineWebber Development Corporation and later a member of PaineWebber Inc.’s Board of Directors.
In 1990, Mr. Evans-Freke founded Selectide Corporation, where he served as Chairman until its sale to Hoechst in 1994. In 1991, he founded SUGEN, a drug discovery company, and served as Chairman and Chief Executive Officer through its IPO in 1995 until its sale to Pharmacia in 1999. Mr. Evans-Freke was also a co-founder of Fibrogen, Inc., Royalty Pharma AG, and CIBUS Global LLC, serving as Chairman of the latter until 2013.